Rinvoq and Oral Contraception
Upadacitinib (Rinvoq) does not affect the effectiveness of combined estrogen-progestin oral contraceptive pills, and no dose adjustments or additional contraception methods are required when using these medications together.
Drug Interaction Evidence
The FDA label for Rinvoq explicitly addresses contraception requirements but does not list oral contraceptives as having any drug-drug interactions 1. More importantly, a dedicated pharmacokinetic study demonstrated that upadacitinib has no clinically significant effect on the metabolism or blood levels of oral contraceptives 2.
Key Pharmacokinetic Data
The study evaluated 30 mg once-daily upadacitinib (the standard dose for many indications) with ethinylestradiol/levonorgestrel (0.03/0.15 mg) and found 2:
- Ethinylestradiol exposure: 96% of baseline for maximum concentration, 110% for total exposure (both within bioequivalence range)
- Levonorgestrel exposure: 96% for both maximum concentration and total exposure
- Half-life unchanged: No alteration in how quickly the contraceptive hormones are eliminated
- Conclusion: The oral contraceptives were bioequivalent whether taken with or without upadacitinib
This means the contraceptive efficacy remains fully intact.
Contraception Requirements While on Rinvoq
Despite the lack of drug interaction, the FDA label mandates effective contraception during Rinvoq treatment due to teratogenic risk 1. Specifically:
- Verify pregnancy status before starting treatment
- Use effective contraception during treatment and for 4 weeks after the final dose
- This requirement is based on animal studies showing embryo-fetal harm (skeletal malformations, cardiovascular defects, embryolethality)
Important Context
Combined oral contraceptives qualify as "effective contraception" for this purpose. The 4-week post-treatment contraception window reflects upadacitinib's elimination half-life (8-14 hours), with the extended period providing a safety margin 1.
Clinical Implications
You can confidently prescribe or continue combined oral contraceptives in patients taking Rinvoq without any modifications. The oral contraceptive will:
- Maintain its contraceptive effectiveness
- Fulfill the FDA requirement for effective contraception during Rinvoq therapy
- Require no dose adjustment
Common Pitfall to Avoid
Do not confuse the requirement for contraception (due to teratogenic risk) with a drug interaction affecting contraceptive efficacy. These are separate issues. Rinvoq requires contraception but doesn't interfere with how oral contraceptives work.
Special Populations
For patients with systemic lupus erythematosus or antiphospholipid antibody syndrome who might be prescribed Rinvoq, note that combined estrogen-progestin contraceptives may be contraindicated due to the underlying disease, not due to Rinvoq itself 3. In such cases, consider progestin-only methods or IUDs as alternatives that still provide effective contraception while on Rinvoq.